Evaluate the Migration Potential of Xeomin® Compared to Two Other Botulinum Toxin Type A Products
Phase 1
Completed
- Conditions
- Healthy
- Registration Number
- NCT00515944
- Lead Sponsor
- Merz Pharmaceuticals GmbH
- Brief Summary
Xeomin® is a Botulinum neurotoxin type A preparation free of complexing proteins, i.e. free of bacterial proteins other than the active toxin. Injected into the muscle, Xeomin® causes local weakening. Botulinum toxin type A is used for certain neurological and aesthetic treatments. This study will investigate the migration potential of Xeomin®.
- Detailed Description
Conducted in Europe
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 30
Inclusion Criteria
- Healthy females, 18 to 65 years
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Measurement of area
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Merz Pharmaceuticals GmbH
🇩🇪Frankfurt am Main, Germany